New hope for tough pancreatic cancer: immunotherapy combo trial shows promise

NCT ID NCT04787991

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 26 times

Summary

This early-phase trial tested combinations of immunotherapy drugs with standard chemotherapy in 45 people whose pancreatic cancer had spread. The goal was to see if these combos are safe and help shrink tumors. While not a cure, the study aims to improve disease control for this aggressive cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • M.D. Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Stanford University

    Stanford, California, 94305, United States

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.